Skip to main content

Table 2 Pulmonary lavage values

From: Nebulized heparin is associated with fewer days of mechanical ventilation in critically ill patients: a randomized controlled trial

  Baseline Day 1 Day 2 Day 4
  Placebo
N = 25
Heparin
N = 25
Placebo
N = 24
Heparin
N = 24
Placebo
N = 22
Heparin
N = 20
Placebo
N = 18
Heparin
N = 14
TAT, μg/L 13.9 (6.2-37.9) 8.7 (3.5-30.0) 7.8 (4.9-20.7) 8.1 (3.5-17.3) 9.3 (3.9-15.7) 7.3 (3.1-20.3) 7.9 (4.3-11.0) 7.2 (2.6-18.4)
D-dimer, mg/L 3.1 ± 6.3 2.4 ± 7.5 5.4 ± 11.3 2.8 ± 7.8 1.3 ± 2.0 0.67 ± 1.1 0.67 ± 1.1 0.52 ± 0.54
IL-6, pg/mL 235 (44-1,699) 187 (34-961) 173 (71-547) 182 (58-589) 132 (36-497) 105 (27-478) 90 (34-313) 60 (23-227)
IL-8, pg/mL 546 (219-1,383) 559 (198-11,949) 667 (255-2,633) 1,396 (333-6,009) 874 (381-1,901) 1328 (369-2,895) 691 (234-1,307) 1,035 (246-1,812)
TNFα, pg/mL 11.8 ± 19.5 9.3 ± 12.7 7.3 ± 10.2 4.9 ± 7.3 5.9 ± 8.9 6.8 ± 13.3 7.9 ± 9.9 6.4 ± 7.9
SP-D, ng/mL 162.6 (44.7-602.3) 309.7 (51.7-805.9) 305.1 (65.3-662.1) 210.5 (36.0-901.5) 153.8 (82.7-823.2) 119.2 (78.4-368.1) 136.1 (85.5-309.4) 176.6 (43.8-399.6)
CC-16, ng/mL 180.0 ± 148.6 207.2 ± 137.8 176.8 ± 155.7 172.4 ± 123.7 225.5 ± 148.6 186.5 ± 150.0 229.8 ± 142.6 207.4 ± 237.9
RAGE, pg/mL 2,015 ± 3,607 3,170 ± 5,428 3,717 ± 11,072 3,320 ± 6,472 1,564 ± 3,273 1,975 ± 3,633 563 ± 1,369 936 ± 1,737
  1. Values are presented as median and interquartile range (there were no statistical differences between groups, and comparisons were undertaken at baseline and study days 1, 2, and 4) or as mean ± standard deviation. CC-16, Clara cell protein-16; IL, interleukin; RAGE, receptor for advanced glycation end-products; SP-D, surfactant protein-D; TAT, thrombin-antithrombin complex; TNFα, tumor necrosis factor-alpha.